Statins
The best-researched class of LDL-cholesterol-lowering drugs, with one of the largest evidence bases in all of cardiology — yet still surrounded by numerous, largely unfounded fears.
Number of studies
1
Safety
Moderate
Time to effects
LDL reduction is visible on blood tests after 4–6 weeks of use; the reduction in clinical risk builds up with long-term use.
Who it's for
Table of contents
TL;DR
The best-researched class of LDL-cholesterol-lowering drugs, with one of the largest evidence bases in all of cardiology — yet still surrounded by numerous, largely unfounded fears.
- →Effectively and predictably lowers LDL cholesterol
- →Reduces the risk of heart attack, stroke, and cardiovascular death, confirmed in dozens of randomized trials
- →Shows additional plaque-stabilizing effects independent of cholesterol lowering itself
| Drug type | HMG-CoA reductase inhibitor, a class of lipid-lowering drugs |
|---|---|
| Level of evidence | Very strong — one of the most thoroughly researched drug classes in medicine |
| Target group | People with elevated cardiovascular risk or a prior event |
| Effect | LDL reduction of 20–60% depending on the substance and dose |
| Status | Prescription drug, used under a doctor's supervision |
Understand
Overview
Statins are a class of drugs that inhibit the enzyme HMG-CoA reductase, key to hepatic cholesterol synthesis, thereby lowering LDL cholesterol levels in the blood. They are one of the most thoroughly studied drug groups in all of medicine — the Cholesterol Treatment Trialists' Collaboration meta-analysis, covering data from dozens of randomized trials and hundreds of thousands of patients, clearly showed that lowering LDL by each unit translates into a proportional reduction in the risk of major cardiovascular events.
Despite this solid evidence base, statins are the subject of numerous fears, partly driven by rare side effects that receive outsized media attention. The actual incidence of serious adverse effects (such as significant muscle damage) is, in placebo-controlled trials, considerably lower than subjective reports under open-label use would suggest — a phenomenon called the nocebo effect, where mere awareness of taking a statin increases the reporting of muscle complaints regardless of the drug's actual action.
Who can genuinely benefit from this? People with elevated cardiovascular risk for whom lifestyle changes alone proved insufficient to reach their target LDL level, and people who have had a prior cardiovascular event (secondary prevention), where the benefits of statins are especially well documented.
Mechanism of action
Statins competitively inhibit HMG-CoA reductase, the enzyme catalyzing the rate-limiting step in intracellular cholesterol synthesis in the liver. Lowering intracellular cholesterol triggers a compensatory increase in the number of LDL receptors on the surface of hepatocytes, increasing uptake of circulating LDL from the bloodstream into the liver and lowering its serum concentration.
Beyond lowering LDL, statins also show pleiotropic effects independent of cholesterol itself — they stabilize atherosclerotic plaques, reduce inflammation in the vessel wall, and improve endothelial function, which partly explains why clinical benefits appear faster than the pace of lipid profile change alone would suggest.
Inhibiting HMG-CoA reductase
Statins block a key enzyme in intracellular cholesterol synthesis in the liver.
Increase in LDL receptors
Lowering intracellular cholesterol increases LDL uptake from the bloodstream by the liver.
Pleiotropic effects
Statins stabilize atherosclerotic plaques and reduce inflammation independent of LDL lowering itself.
Evidence: strong — based on 1 study in this database.
Benefits
Common myths
MythStatins always cause severe muscle pain.
FactPlacebo-controlled (double-blind) studies show a considerably lower rate of real, objectively confirmed muscle complaints than subjective reports under open-label use suggest — a phenomenon known as the nocebo effect.
MythStatins are only needed with very high cholesterol.
FactThe decision to start a statin is based on an overall assessment of cardiovascular risk, not cholesterol value alone — in high-risk people, benefit can occur even with only moderately elevated LDL.
Forms & variants
Statins comes in several forms that differ in bioavailability and use case — the form you pick genuinely matters for how effective the supplementation is.
Atorvastatin, rosuvastatin
High-intensity statins with a stronger LDL-lowering effect.
Best for: High cardiovascular risk, secondary prevention
Simvastatin, pravastatin
Moderate-intensity statins.
Best for: Moderate risk or poorer tolerance of stronger statins
Practice
Frequently asked questions
In most cases, yes, because their effect depends on continuous use — stopping the drug usually leads cholesterol to return to pre-treatment values.
No over-the-counter supplement has a comparably solid evidence base for reducing cardiovascular risk as statins — any decision to switch should always be discussed with a doctor.
It's worth reporting it to your doctor, who can change the substance, dose, or dosing schedule — in many cases the complaints resolve after such a modification.
What to combine with
Good combinations
Lipid Panel — The effectiveness of statin therapy is monitored through regular follow-up lipid panel testing
Safety
Side effects & contraindications
Possible side effects
Muscle pain — in some people, though less often than subjective reports suggest (nocebo effect)
Rarely: elevated liver enzymes, requiring monitoring
Very rarely: rhabdomyolysis (serious muscle damage)
Contraindications
Active liver disease
Pregnancy and breastfeeding
Interactions
Certain antibiotics and antifungal drugs can increase statin blood levels
Large amounts of grapefruit juice can increase the levels of certain statins
Is it worth taking?
Who it's for
- People with elevated cardiovascular risk despite lifestyle changes
- People who have had a prior heart attack or stroke (secondary prevention)
Not for
- Active liver disease
- Pregnancy and breastfeeding
Evidence
Worth knowing
The CTT meta-analysis covered data from more than 170,000 participants of randomized statin trials.
Statins lower LDL by 20–60%, depending on the specific substance and dose used.
Studies
Lowering LDL concentration by each unit through statin therapy translates into a proportional reduction in the risk of major cardiovascular events, regardless of baseline cholesterol level.
Cholesterol Treatment Trialists' (CTT) Collaboration, The Lancet, 2010
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials
Strong evidenceCholesterol Treatment Trialists' (CTT) Collaboration · The Lancet · 2010
A meta-analysis of 26 randomized trials showing that statin-driven LDL reduction translates into a proportional reduction in the risk of major cardiovascular events.
View studySources & bibliography
Citations are illustrative for this demo version and require full bibliographic verification by the editorial team before production publication.
Compare with similar entries
About the authors of this entry
Author
dr Piotr ZielińskiEndocrinologist
Piotr reviews content on hormones, metabolic health and supplement pharmacology.
131 publications on this site
Medical review
dr Anna KowalczykEditor-in-Chief, Molecular Biology
Anna oversees the editorial process and scientific review of every publication in the knowledge base. She previously researched autophagy and mitochondrial biology.
50 publications on this site
Related entries
4.6Lipid Panel
The lipid panel is one of the most important — and still one of the most frequently misread — preventive blood tests: 'total cholesterol' alone tells you less than the ratios between its fractions.
4.5Metformin
The most commonly prescribed drug for type 2 diabetes in the world — with a well-understood metabolic mechanism and an intensively studied, but still unproven, potential to slow aging.
4.6Metabolic Syndrome
A cluster of five risk factors — from abdominal obesity to elevated triglycerides — that multiplies the risk of type 2 diabetes and cardiovascular disease, but is largely modifiable through lifestyle change.
4.5How to Read a Basic Blood Test Panel
CBC, lipid panel, glucose, TSH — how to read the results of a basic blood panel so you catch early signals of a problem before it becomes a disease.
4.5TRT and Cholesterol — How Does Testosterone Affect Your Lipid Profile?
Testosterone therapy usually lowers total cholesterol and LDL slightly, but it often lowers HDL too — which historically raised concern. We explain why these changes rarely translate into a real worsening of cardiovascular risk, and how to read a lipid panel in the context of TRT.
4.3Shiitake
A culinary-functional mushroom rich in lentinan and beta-glucans, studied clinically for immune modulation and lipid profile — one of the best-researched functional mushrooms on the market.
4.3Oyster Mushroom (Pleurotus ostreatus)
One of the most popular edible mushrooms in Poland, containing a natural compound structurally similar to lovastatin — studied mainly for its effects on lipid profile and immunity.
4.3PSA and Prostate Health
Prostate-specific antigen is one of the most commonly ordered tests in men over 50 — but also one of the most controversial, due to a high false-positive rate.
Related articles
PoradnikiMuscle Pain from Statins: Drug Effect or Nocebo?
Millions of patients stop taking statins because of muscle pain that, according to the first trial ever designed to settle the question, has nothing to do with the drug's pharmacology in 90% of cases. In the SAMSON experiment, participants reported nearly identical pain severity while taking the statin and while taking a placebo. That doesn't mean the pain is 'imaginary' — it means the pill itself, not its active ingredient, is usually not the source.
August 23, 2026
PoradnikiGarlic and LDL Cholesterol: Does It Really Lower It?
"Garlic lowers cholesterol" is one of the oldest folk health tips — and, rare for this category, partly confirmed by meta-analyses of clinical trials. But the devil is in the details: the effect is real (an LDL drop of about 9 mg/dL), yet it applies only to people with already elevated cholesterol, requires supplementation lasting more than 2 months, and has nothing to do with occasionally tossing a clove of garlic into dinner.
August 23, 2026
PoradnikiStatins and Type 2 Diabetes Risk: Do Cholesterol Drugs Raise Your Risk?
Statins are among the most widely prescribed drugs on earth, and their benefit in preventing heart attacks and strokes is one of the best-documented facts in all of cardiology. Less often discussed is another well-confirmed effect: statins genuinely increase the risk of newly diagnosed type 2 diabetes — not a fringe finding from a single study, but a result confirmed independently in the randomized JUPITER trial and in a meta-analysis of 13 trials covering more than 91,000 participants. The key, often-missed nuance is different from what the headline suggests: the increased risk falls almost entirely on people who already had diabetes risk factors, and the cardiovascular benefit of statins — even in that same group — is several times larger than the risk of causing one extra case of diabetes. This article explains why both facts are true at once, and why the authors of both studies, despite confirming the effect, unambiguously recommend continuing statin therapy.
August 25, 2026
Poradniki5 Biomarkers Worth Knowing Before 40 — Signals Before Symptoms Appear
A standard "once-a-year blood count" often misses early signs of metabolic and hormonal issues. Here are five markers worth asking your doctor about, before anything starts to hurt.
August 1, 2026
Comments (2)
- KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
- MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.